On December 11, 2025, Celcuity Inc. (Nasdaq: CELC) disclosed fresh findings from the Phase 3 VIKTORIA-1 trial for gedatolisib, a PAM inhibitor, aimed at developing targeted therapies for oncology. The trial, focused on adults with HR+, HER2-, PIK3CA WT, ABC post-treatment with CDK4/6 and aromatase inhibitors, revealed promising outcomes. The updates were shared at the 2025 San Antonio Breast Cancer Symposium. These results mark a significant step in advancing treatment for this patient population.